Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Abediterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 20/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 17/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Abediterol SCHEMBL29350050 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CHRM3 | |
| Abediterol SCHEMBL241483 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CHRM3 | |
| Abediterol SCHEMBL508916 | 0.97 | ADRB2 (0.94) | ADRB2ADRB1CHRM3 | |
| Abediterol SCHEMBL508915 | 0.97 | ADRB2 (0.94) | ADRB2ADRB1CHRM3 | |
| SCHEMBL15280091 | 0.92 | ADRB2 (0.84) | ADRB2ADRB1CHRM3 | |
| SCHEMBL15280150 | 0.92 | ADRB2 (0.84) | ADRB2ADRB1CHRM3 | |
| SCHEMBL13202777 | 0.91 | ADRB2 (0.83) | ADRB2ADRB1CHRM3 | |
| SCHEMBL19417121 | 0.90 | ADRB2 (0.82) | ADRB2ADRB1CHRM3 | |
| SCHEMBL2758564 | 0.89 | ADRB2 (0.80) | ADRB2ADRB1CHRM3 | |
| SCHEMBL2758562 | 0.89 | ADRB2 (0.80) | ADRB2ADRB1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 351 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2828242-B1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYLATE AS AGONIST OF THE ß2 ADRENERGIC RECEPTOR. | ALMIRALL SA (ES) | 2017-10-04 | — | — | EP | claimed |
| US-9346759-B2 | Polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisytlate as agonist of the β2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2016-05-24 | — | — | US | claimed |
| US-9108918-B2 | Process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one via a novel intermediate | ALMIRALL, S.A. (ES) | 2015-08-18 | — | — | US | claimed |
| US-20150057256-A1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2--1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYTLATE AS AGONIST OF THE BETA2 ADRENERGIC RECEPTOR | ALMIRALL S.A. (ES) | 2015-02-26 | — | — | US | claimed |
| US-20150011769-A1 | PROCESS FOR PREPARING 5-(2--1(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE VIA A NOVEL INTERMEDIATE | ALMIRALL, S.A. (ES) | 2015-01-08 | — | — | US | claimed |
| US-20140343097-A1 | 5-(2-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE FOR THE TREATMENT OF LUNG FUNCTION | ALMIRALL, S.A. (ES) | 2014-11-20 | — | — | US | claimed |
| US-20140038928-A1 | 5-(2--1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2 (1H)-ONE AND ITS USE IN THE TREATMENT OF PULMONARY DISEASES | ALMIRALL, S.A. (ES) | 2014-02-06 | — | — | US | claimed |
| US-8563731-B2 | Mesylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]jamino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one as agonist of the β2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2013-10-22 | — | — | US | claimed |
| EP-2641900-A1 | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. | Almirall, S.A. (ES) | 2013-09-25 | — | — | EP | claimed |
| US-8524908-B2 | Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one | ALMIRALL, S.A. (ES) | 2013-09-03 | — | — | US | claimed |
| EP-2228368-A1 | Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one | Almirall, S.A. (ES) | 2010-09-15 | — | — | EP | claimed |
| WO-2010094484-A1 | 5- (2-{ [6- (2, 2-DIFLUORO-2-PHENYLETHOXY) HEXYL] AMINO}-L-HYDROXYETHYL) -8-HYDROXYQUIN OLIN-2 (1H)-ONE AND ITS USE IN THE TREATMENT OF PULMONARY DISEASES | ALMIRALL, S.A. (ES) | 2010-08-26 | — | — | WO | claimed |
| WO-2010094483-A1 | 5- (2-{ [6- (2, 2-DIFLUORO-2-PHENYLETHOXY) HEXYL] AMINO} -1-HYDROXYETHYL) -8-HYDROXYQUINOLIN-2 (IH)-ONE FOR THE TREATMENT OF LUNG FUNCTION | ALMIRALL, S.A. (ES) | 2010-08-26 | — | — | WO | claimed |
| EP-2221055-A1 | 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function | Almirall, S.A. (ES) | 2010-08-25 | — | — | EP | claimed |
| EP-2221297-A1 | 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases | Almirall, S.A. (ES) | 2010-08-25 | — | — | EP | claimed |
| WO-2010072354-A1 | MESYLATE SALT OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO }-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE β2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2010-07-01 | — | — | WO | claimed |
| US-20100093681-A1 | NAPADISYLATE SALT OF 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2010-04-15 | — | — | US | claimed |
| EP-2121615-A1 | NAPADISYLATE SALT OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | Almirall, S.A. (ES) | 2009-11-25 | — | — | EP | claimed |
| US-20090042933-A1 | Derivatives of 4-(2-amino -1-hydroxyethyl)phenol as agonists of the Beta2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2009-02-12 | — | — | US | claimed |
| WO-2008095720-A1 | NAPADISYLATE SALT OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2008-08-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011769-A1 | PROCESS FOR PREPARING 5-(2--1(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE VIA A NOVEL INTERMEDIATE | UGT1A8, UGT1A1, UGT8 | ADRB2 411/4885ADRB1 493/4885CHRM3 3957/4885 |
| US-20140038928-A1 | 5-(2--1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2 (1H)-ONE AND ITS USE IN THE TREATMENT OF PULMONARY DISEASES | ADRB2, ADRA2C, ADRB1 | ADRB2 1/4885ADRB1 3/4885CHRM3 23/4885 |
| US-20140343097-A1 | 5-(2-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE FOR THE TREATMENT OF LUNG FUNCTION | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP11B2, CYP27A1 | ADRB2 194/4885ADRB1 193/4885CHRM3 279/4885 |
| US-20090042933-A1 | Derivatives of 4-(2-amino -1-hydroxyethyl)phenol as agonists of the Beta2 adrenergic receptor | ADRB2, ADRA2C, ADRB1 | ADRB2 1/4885ADRB1 3/4885CHRM3 14/4885 |
| US-20150057256-A1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2--1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYTLATE AS AGONIST OF THE BETA2 ADRENERGIC RECEPTOR | ADRA2C, ADRB2, ADRA2A | ADRB2 2/4885ADRB1 5/4885CHRM3 43/4885 |
| US-20100093681-A1 | NAPADISYLATE SALT OF 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | ADRA2C, ADRB2, ADRA2A | ADRB2 2/4885ADRB1 4/4885CHRM3 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.